{
    "2019-05-22": [
        [
            {
                "time": "2018-09-15",
                "original_text": "Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "gene therapy",
                        "price",
                        "lower",
                        "million"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-15",
                "original_text": "Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Difficult",
                        "Stock",
                        "Trade",
                        "Own",
                        "Risk"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-15",
                "original_text": "The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Tocagen",
                        "OncoSec",
                        "Offering",
                        "Novartis",
                        "Asthma",
                        "Combo",
                        "Drug",
                        "Study"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-15",
                "original_text": "3 Bearish Takeaways From the Tilray Earnings Report",
                "features": {
                    "keywords": [
                        "Bearish",
                        "Takeaways",
                        "Tilray",
                        "Earnings",
                        "Report"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}